10:42 AM EST, 11/25/2025 (MT Newswires) -- Lunai Bioworks ( LNAI ) shares were up 5% in Tuesday trading after it received a letter of intent to license its immune cell therapy, which showed complete tumor regression with no recurrence in humanized pancreatic cancer models.

The company said the results follow a successful pre-IND meeting with the US Food and Drug Administration and a peer-reviewed publication highlighting its DCCT platform's multi-pathway immune activation.

Lunai added that two independent studies showed up to a 90% reduction in tumor size, with remaining tissue largely composed of immune cells, based on analysis by the late UCLA professor Anahid Jewett.

The platform uses healthy donor dendritic cells in an off-the-shelf model that cuts production time and cost, Lunai said.

The company said it is preparing for licensing talks and further pre-IND activities in early 2026 as it plans phase I trials targeting solid tumors.

Price: 1.34, Change: +0.07, Percent Change: +5.51